MERS-CoV Spike Protein (E6Q5A) Rabbit mAb #41859
- WB
Supporting Data
| REACTIVITY | Vir |
| SENSITIVITY | Transfected Only |
| MW (kDa) | 200, 120 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- Vir-Virus
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
Storage
Protocol
Specificity / Sensitivity
MERS-CoV Spike Protein (E6Q5A) Rabbit mAb recognizes transfected levels of total MERS-CoV spike protein. The antibody detects full-length MERS-CoV spike protein and also detects the S1 fragment generated by host protease cleavage. It does not cross-react with spike proteins from SARS coronaviruses (CoV-1, CoV-2).
Species Reactivity:
Virus
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human MERS-CoV spike protein.
Background
Middle East Respiratory Syndrome (MERS) is a contagious viral respiratory infection, whose causative agent was identified as the MERS-related coronavirus (MERS-CoV) (1,2). MERS-CoV is a single-stranded mRNA betacoronavirus; similar to other infectious coronaviruses (e.g., SARS-CoV-2), the MERS-CoV virion is comprised of four key structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N) (3). Coronavirus spike proteins are class I fusion proteins that harbor an ectodomain, a transmembrane domain, and an intracellular tail. The highly glycosylated ectodomain projects from the viral envelope surface and facilitates attachment and fusion with the host cell plasma membrane. The ectodomain can be further subdivided into host receptor-binding domain (RBD) (S1) and membrane-fusion (S2) subunits, which are produced upon proteolysis by host proteases (4). MERS-CoV spike proteins utilize the cell surface protein DPP4/CD26 as the receptor for cellular entry (5,6); notably, this protein displays no structural similarities to ACE2, the primary receptor for SARS-CoV-1 and SARS-CoV-2. Spike protein subunits represent a key antigenic feature of coronavirus virions, and therefore represent an important target of vaccines, novel therapeutic antibodies, and small-molecule inhibitors (7,8).
- Bermingham, A. et al. (2012) Euro Surveill 17, 20290.
- de Groot, R.J. et al. (2013) J Virol 87, 7790-2.
- van Boheemen, S. et al. (2012) mBio 3, e00473-12. doi: 10.1128/mBio.00473-12.
- Jiang, S. et al. (2013) J Infect 66, 464-6.
- Wang, N. et al. (2013) Cell Res 23, 986-93.
- Raj, V.S. et al. (2013) Nature 495, 251-4.
- Du, L. et al. (2009) Nat Rev Microbiol 7, 226-36.
- Yuan, Y. et al. (2017) Nat Commun 8, 15092.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.